GameChangers

Geoff Wall, PharmD & Jamie Pitlick, PharmD discussing SGLT2 inhibitors, also called gliflozins, are a class of medications that inhibit reabsorption of glucose in the kidney and therefore lower blood sugar.  Recently SGLTs, which are currently indicated for Type 2 diabetes, have been investigated and received FDA approval for Heart failure with reduced ejection fraction (HFrEF).  Listen in to this episode to discover more about how these drugs work in this (HFrEF) disease state.

This episode is accredited for CPE.  This episode is accredited for CPE.  For CE details and to claim credit click here:  https://bit.ly/2ApMvWw 

See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices

GameChangers: In this episode, we describe the latest information concerning hypercoagulability with COVID-19 infection.  In this episode, we describe the latest information concerning hypercoagulability with COVID-19 infection.  Emerging evidence suggests that patients with COVID infection may be hypercoagulable and prone to clotting. Listen in as we discuss the evidence surrounding this issue and how to address therapeutic issues in anticoagulation in this population.

This episode is accredited for CPE.  This episode is accredited for CPE.  For CE details and to claim credit click here:  https://bit.ly/3he73SF 

See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices